Follow
Adam Brufsky
Adam Brufsky
Professor of Medicine, University of Pittsburgh
Verified email at upmc.edu
Title
Cited by
Cited by
Year
Comprehensive molecular portraits of human breast tumours
D Koboldt, R Fulton, M McLellan, H Schmidt, J Kalicki-Veizer, ...
Nature 490 (7418), 61-70, 2012
89362012
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 379 (2), 111-121, 2018
13262018
Prospective validation of a 21-gene expression assay in breast cancer
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
12172015
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
10622011
The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
E Giovannucci, MJ Stampfer, K Krithivas, M Brown, A Brufsky, J Talcott, ...
Proceedings of the National Academy of Sciences 94 (7), 3320-3323, 1997
10381997
Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ...
Clinical cancer research 15 (4), 1452-1459, 2009
6512009
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with …
S Chia, W Gradishar, L Mauriac, J Bines, F Amant, M Federico, L Fein, ...
Journal of clinical oncology 26 (10), 1664-1670, 2008
6152008
Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3
TY Kim, GM Kim, M Martín, C Zielinski, M Ruíz-borrego, E Carrasco, ...
Journal of Clinical Oncology, 32-45, 2019
5842019
Zoledronic acid inhibits adjuvant letrozole–induced bone loss in postmenopausal women with early breast cancer
A Brufsky, WG Harker, JT Beck, R Carroll, E Tan-Chiu, C Seidler, ...
Journal of Clinical Oncology 25 (7), 829-836, 2007
5792007
Bevacizumab added to neoadjuvant chemotherapy for breast cancer
HD Bear, G Tang, P Rastogi, CE Geyer Jr, A Robidoux, JN Atkins, ...
New England Journal of Medicine 366 (4), 310-320, 2012
5102012
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus …
EH Romond, JH Jeong, P Rastogi, SM Swain, CE Geyer Jr, MS Ewer, ...
Journal of Clinical Oncology 30 (31), 3792, 2012
4872012
RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line …
AM Brufsky, S Hurvitz, E Perez, R Swamy, V Valero, V O'Neill, HS Rugo
Journal of clinical oncology 29 (32), 4286-4293, 2011
4302011
Cognitive impairment associated with adjuvant therapy in breast cancer
CM Bender, SM Sereika, SL Berga, VG Vogel, AM Brufsky, KK Paraska, ...
Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2006
4072006
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial
A Robidoux, G Tang, P Rastogi, CE Geyer Jr, CA Azar, JN Atkins, ...
The lancet oncology 14 (12), 1183-1192, 2013
3672013
Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER
AM Brufsky, M Mayer, HS Rugo, PA Kaufman, E Tan-Chiu, D Tripathy, ...
Clinical Cancer Research 17 (14), 4834-4843, 2011
3252011
Practical guidance for the management of aromatase inhibitor-associated bone loss
P Hadji, JJ Body, MS Aapro, A Brufsky, RE Coleman, T Guise, A Lipton, ...
Annals of Oncology 19 (8), 1407-1416, 2008
2832008
Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer
JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ...
New England Journal of Medicine 380 (25), 2395-2405, 2019
2612019
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
JA Low, SB Wedam, JJ Lee, AW Berman, A Brufsky, SX Yang, ...
Journal of Clinical Oncology 23 (12), 2726-2734, 2005
2542005
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally …
NJ Robert, V Diéras, J Glaspy, A Brufsky, I Bondarenko, O Lipatov, ...
Journal of Clinical Oncology 27 (15_suppl), 1005-1005, 2009
2462009
Zoledronic acid effectively prevents aromatase inhibitor–associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36 …
AM Brufsky, LD Bosserman, RR Caradonna, BB Haley, CM Jones, ...
Clinical breast cancer 9 (2), 77-85, 2009
2322009
The system can't perform the operation now. Try again later.
Articles 1–20